臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"ann lii cheng"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 421-445 / 690 (共28頁)
<< < 12 13 14 15 16 17 18 19 20 21 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-08-31T06:29:44Z	BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer	Chen K.-H.; Lin Y.-L.; Liau J.-Y.; Tsai J.-H.; Tseng L.-H.; Lin L.-I.; Liang J.-T.; Lin B.-R.; Hung J.-S.; Chang Y.-L.; Yeh K.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:44Z	Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis	Chen I.-C.; Lin C.-H.; Jan I.-S.; ANN-LII CHENG; Lu Y.-S.
臺大學術典藏	2021-08-31T06:29:44Z	Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges	Lu L.-C.; Hsu C.-H.; Hsu C.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:43Z	A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer	Chen B.-B.; Lu Y.-S.; Lin C.-H.; Chen W.-W.; Wu P.-F.; Hsu C.-Y.; Yu C.-W.; Wei S.-Y.; ANN-LII CHENG; Shih T.T.-F.
臺大學術典藏	2021-08-31T06:29:43Z	Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:43Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2021-08-31T06:29:43Z	Cyclin E1 inhibition can overcome sorafenib resistance in hepatocellular carcinoma cells through Mcl-1 suppression	Hsu C.; Lin L.-I.; Cheng Y.-C.; Feng Z.-R.; Shao Y.-Y.; ANN-LII CHENG; Ou D.-L.
臺大學術典藏	2021-08-31T06:29:42Z	Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1�V2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy	Lai S.-F.; Chen Y.-H.; Kuo W.-H.; Lien H.-C.; Wang M.-Y.; Lu Y.-S.; Lo C.; Kuo S.-H.; ANN-LII CHENG; Huang C.-S.
臺大學術典藏	2021-08-31T06:29:42Z	Inhibition of the Wnt/�]-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma	Lin H.-H.; Feng W.-C.; Lu L.-C.; Shao Y.-Y.; Hsu C.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:42Z	Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer	Yang S.-H.; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏	2021-08-31T06:29:42Z	A phase i clinical study of immunotherapy for advanced colorectal cancers using carcinoembryonic antigen-pulsed dendritic cells mixed with tetanus toxoid and subsequent IL-2 treatment John T Kung	Liu K.-J.; Chao T.-Y.; Chang J.-Y.; ANN-LII CHENG; Ch'Ang H.-J.; Kao W.-Y.; Wu Y.-C.; Yu W.-L.; Chung T.-R.; Whang-Peng J.
臺大學術典藏	2021-08-31T06:29:41Z	Tumor compactness improves the preoperative volumetrybased prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy	Hsu C.-Y.; Wang C.-W.; Kuo C.-C.; Chen Y.-H.; Lan K.-H.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏	2021-08-31T06:29:41Z	Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma	Yang C.W.-C.; Wang C.-W.; Hong R.-L.; Tsai C.-L.; Yao M.; Tang J.-L.; Lin C.-W.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏	2021-08-31T06:29:41Z	Association of radiotherapy with favorable prognosis in daily clinical practice for treatment of locally advanced and metastatic pancreatic cancer	Yang S.-H.; Guo J.-C.; Yeh K.-H.; Tien Y.-W.; ANN-LII CHENG; Kuo S.-H.
臺大學術典藏	2021-08-31T06:29:40Z	Chemotherapy alone is an alternative treatment in treating localized primary ocular adnexal lymphomas	Ma W.-L.; Yao M.; Liao S.-L.; Tang J.-L.; Wang Y.-C.; Kuo S.-H.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:40Z	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial	Bruix J.; Qin S.; Merle P.; Granito A.; Huang Y.-H.; Bodoky G.; Pracht M.; Yokosuka O.; Rosmorduc O.; Breder V.; Gerolami R.; Masi G.; Ross P.J.; Song T.; Bronowicki J.-P.; Ollivier-Hourmand I.; Kudo M.; ANN-LII CHENG; Llovet J.M.; Finn R.S.; LeBerre M.-A.; Baumhauer A.; Meinhardt G.; Han G.
臺大學術典藏	2021-08-31T06:29:40Z	Irinotecan and oxaliplatin might provide equal benefit as adjuvant chemotherapy for patients with resectable synchronous colon cancer and liver-confined metastases: A nationwide database study	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; ANN-LII CHENG; Lai M.-S.; Yeh K.-H.
臺大學術典藏	2021-08-31T06:29:39Z	The B-cell-activating factor signalling pathway is associated with Helicobacter pylori independence in gastric mucosa-associated lymphoid tissue lymphoma without t(11;18)(q21;q21)	Kuo S.-H.; Tsai H.-J.; Lin C.-W.; Yeh K.-H.; Lee H.-W.; Wei M.-F.; Shun C.-T.; Wu M.-S.; Hsu P.-N.; Chen L.-T.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:39Z	Do-not-resuscitate consent signed by patients indicates a more favorable quality of end-of-life care for patients with advanced cancer	Liang Y.-H.; Wei C.-H.; Hsu W.-H.; Shao Y.-Y.; Lin Y.-C.; Chou P.-C.; ANN-LII CHENG; Yeh K.-H.
臺大學術典藏	2021-08-31T06:29:39Z	Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL	Kuo S.-H.; Chen L.-T.; Lin C.-W.; Yeh K.-H.; Shun C.-T.; Tzeng Y.-S.; Liou J.-M.; Wu M.-S.; Hsu P.-N.; ANN-LII CHENG
臺大學術典藏	2021-08-31T06:29:38Z	Corrigendum to ��Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma�� (Journal of Hepatology (2011) 55(5) (1041�V1048)(S0168827811001917)(10.1016/j.jhep.2011.01.047))	Tai W.-T.; ANN-LII CHENG; Shiau C.-W.; Huang H.-P.; Huang J.-W.; Chen P.-J.; Chen K.-F.
臺大學術典藏	2021-08-31T06:29:38Z	Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer	Tsai K.-F.; Liou J.-M.; Chen M.-J.; Chen C.-C.; Kuo S.-H.; Lai I.-R.; Yeh K.-H.; Lin M.-T.; Wang H.-P.; ANN-LII CHENG; Lin J.-T.; Shun C.-T.; Wu M.-S.
臺大學術典藏	2021-08-31T06:29:38Z	Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)	Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; Shao Y.-Y.; Lin Z.-Z.; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG; Carrasquilo J.A.
臺大學術典藏	2021-08-31T06:29:37Z	Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study	ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R.
臺大學術典藏	2021-08-31T06:29:37Z	Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study	Lu L.-C.; Chen P.-J.; Yeh Y.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; Shao Y.-Y.; ANN-LII CHENG

顯示項目 421-445 / 690 (共28頁)
<< < 12 13 14 15 16 17 18 19 20 21 > >>
每頁顯示[10|25|50]項目

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 51124208 線上人數 : 742 教育部委託研究計畫計畫執行:國立臺灣大學圖書館